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Prevalence of YMDD Variants Leading to Lamivudine Resistance among Chronic 
HBV Patients in Gaza Strip-Palestine 
Background: Hepatitis B is an inflammation of the liver caused by hepatitis B virus 
(HBV). It is widely spread in the world, so that there are a variety of antiviral drugs for 
HBV,. In Gaza strip the most commonly used anti- HBV drug is lamivudine. Long term 
use of lamivudine causes mutations; the most common mutations worldwide are rtM204 
V/I/S and rt L180M. The aim of this study is to investigate the prevalence of lamivudine 
resistance among chronic patients in Gaza strip and to determine possible risk factors 
associated with lamivudine resistance. 
Materials and Methods: During this study all patients attending the medical centers in 
Gaza Strip (100 patients) were tested for viral load using Real Time Polymerase Chain 
Reaction (RT-PCR). Fifty
 
four chronic hepatitis B patients with viral load above 4500 
IU/mL
 
were included in the study. Lamivudine resistance for these patients was detected 
via RT-PCR. Data on possible risk factors was completed by the researcher from 
medical records and from calling patients to insure proper data collection. 
 
Results: The prevalence of lamivudine resistance genotypes was divided in this study 
into five groups; the first group is the wild type (YMDD) it was found in  (32.6%) of the 
study population, then YMDD mixed with YIDD was (41.3%), the third was YIDD 
alone it was found in (13%), the fourth YIDD / YVDD was (2.2%), the final group was 
YMDD / YIDD / YVDD patients (10.9%). In addition, No significant relationship 
between YMDD(Wild type), YIDD,YIDD/YVDD,YIDD/ YMDD, and (YMDD /YIDD/ 
YVDD) versus age, sex, lamivudine intake duration, and liver function tests (ALT & 
AST).While a significant relation  was fond between these variables with viral load. As 
well as significance have seen in wild type and mutant type with lamivudine intake 
duration. 
 
Conclusion: Lamivudine resistance was detected among chronic hepatitis B patients, 
therefore,  routine monitoring for such patients in Gaza strip is highly recommended. 
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 المزمن التهاب الكبد الوبائي ) ب( مرضى لدى مقاومة الالموفودين بسبب حدوث  الطفرات تحديد مدى انتشار
 فلسطين - قطاع غزة في
 
رو  روي   عنهو التهاب الكبد الناجم الوبائي ب التهاب الكبد  :المقدمة  فيروو  التهراب الكبرد الوبرائي ,بو و وهرو 
رن رجروعة رتنوعة رن األدوية الرضادة لفي  يوجد ااالنتشاو في العالم ؛ لذ وو  التهاب الكبد الوبرائي ,بو  لكري ت رد 
و  األكثو ا تخدارا رن برين هرذه األدويرة فري  غرا  مراة لركاف رة التهراب الكبرد الوبرائي ,بوو الالروفودين يعد .انتشاوه
رة  لعرال   إظهراوب بب ا تخدارها لردة ارنية غويلة دون تقييم تركن الفيوو  رن  و و  الالروفرودينعردة غفروام رقاو
شريوعا فري جرير   مأكثو الغفروارن  على أنايم البوليرويا 402 غفوة الفالين أو االياولي ين أو ال يوين في رو   تعد
 لنف  األنايم . 080لغفوة الرثيونين  على الرو    إضافةأن اء العالم و 
 
الوا   في أنايم   402في رو    غفوة الفالين أو االياولي ينوالغفوام , تهدف هذه الدوا ة الى تقديو ردى انتشاو
رة الالروفروديالبولير رارن التهراب الكبرد الوبرائي , بو روضرى برينن ويا ب ربب  ردوم رقاو و   غرا  مراة فري ال
 الالروفودين.عوارل الخغو الروتبغة بظهوو هذه الغفوام الرقاورة  لعال  ودوا ة بع 
 
روي و و وترم  000غا  ماة ,الرواكا الغبية في  الروضى الذين اوتادوا  عدد رنشرلم الدوا ة الرواد واألدوام:  
وو ورن ثم تم تقليص العردد الرى أوبعرة PCR-RT, الكري با تخدام غويقة اكثاو ال ر النووي الفيوو  ةت ديد كري
/ ررل فري الدوا رةو وفري النهايرة ترم الكشرف عرن وجرود  IU 4500وخر رين ررن الروضرى ذوو الن ربة العاليرة  فرو   
و أيضا . أخذم PCR-RTال ر النووي , إكثاوهؤالء الروضى بغويقة الالروفودين بين ة  لعال  الغفوام الرقاور
ررن ال ررجالم الغبيررة وبعرر الرقررابالم الشخ ررية واالت رراالم  ررل الخغررو الر ترلررة  بيانررام الروضررى الرتعلقررة بعوا
 بالروضى رن اجل التأكد رن   ة البيانام الرعغاة.
 
و الجرين األ رلي % 6423توا  على خر  فئام: الجرين األ رلي الغفوام ن ردى انتشاوالدوا ة أهوم ظأالنتائج :  
ر  %424 األياولي ينو غفوتي الفالين و %06 األياولي ين و غفوة%2026 ياولي يناألر  غفوة  و  الجين األ لي 
لو  ة ر   العديد رن العواردوا ة العال ة لهذه الفئام الخر ملذلك تر باإلضافة. %0021 األياولي ين ر  غفوة الفالين
رردة العرال  ووظرائف لر م تكرن هنراك أي عال رة ذام داللرة ا  رائية برين هرذه االنروا  الخر رة رر  العررو و الجرن  و 
ر  رردة العرال  برين  كريةي  ين كانم هناك عال ة ر  فالكبدو الفيوو . وكذلك كانم هناك عال ة ذام داللة ا  رائية 
 فوة.الجين األ لي و الجين ذو الغ
 
ترم الكشرف عرن وجرود رقاوررة لالريفيرودين برين روضرى التهراب الكبرد الوبرائي ,بو و بالترالي فر ن الروا برة  :خالصةةال
 الووتينية لهؤالء الروضى أرو رهم.
 
غفروة الفرالينو غفروة لريثرونينوو ,ا و الن رخة األ رلية الكبد الوبرائي , بوفيوو   و رقاورةو روفودينال :الكلمات الدالة
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Hepatitis is an inflammation of the liver caused by microrganisms and toxins. There is a 
variety of viruses such as hepatitis A, B, C, D and E that are involved in the 
pathophysiology of this disease (Harvey et al., 2007).  
 
Hepatitis B virus (HBV) is the most common blood borne viral infection worldwide; 
that is capable of causing hepatitis by attacking the liver leading to acute (transient) and 
chronic infection. Acute infection may cause serious illness and 0.5% terminates with 
fatal, fulminate hepatitis. While chronic infection has serious consequences, about 
twenty five percent terminate to cirrhosis and hepatocellular carcinoma (HCC) 
(Beasley, 1988; Shepard et al., 2006). 
 
World Health Organization estimated in 2002; two billion people worldwide have been 
infected with HBV. More than 350 million are chronic carriers with serious long term 
complication like cirrhosis and hepatocellular carcinoma, and over 4 millions are acute 
carriers (WHO, 2002).Thirty percent of world's population has had contact with or are 
carriers of the hepatitis virus (Stefan et al., 2012).Between 1 and 2 million of this 
population die annually, most of them in Asia (Niesters et al., 2005; Li et al., 2011).   
 
The story of HBV began in 1883 in Bremen, Germany, when Lurman recorded the 
outbreaks of jaundice occurred after weeks following vaccination for smallpox among 
shipyard workers. Then in 1947, MacCallum and Bauer  found the current nomenclature 
of two types of viral hepatitis; hepatitis A virus (Infectious hepatitis) and hepatitis B 
virus (homologous serum hepatitis) (Mahoney, 1999; Shepard et al., 2006) . 
 
In 1965, Dr. Baruch Blumberg and Alter were working at national health institute 
identified the Australia antigen (HBs-Ag) in serum from Australian indigenous  patients 




Finally in 1970, using electron microscopy; Dane and colleagues were the first to detect 
complete hepatitis B virions, or Dane particles (HBV, its surfaces antigen and core 
component) (Mahoney, 1999; Dore et al., 2006; Riu, 2007). Also in 1972 Magnius and 
Espmark discovered the hepatitis e antigen (HBeAg) (Mahoney, 1999). 
 
HBV is distributed worldwide due to rapid transmissions either via percutaneous or 
mucosal exposure by contact with infected blood or body fluids (saliva, blood, 
menstrual and vaginal discharges, seminal fluid, and breast milk) (Baron, 1996; Dore 
et al., 2006; Shepard et al., 2006).  
 
Since the predominance transmission routes differ from country to another; for example 
in Western Europe and low prevalence area, unprotected sexual intercourse and 
intravenous drugs were the dominant route. While in Africa, the most common routes 
are percutaneous contaminated needles and syringes and the preinatal infection from 
mother to her infant (Wong et al., 1984; Kufe et al., 2003; Sablon and Shapiro, 2005; 
Riu, 2007). 
  
The prevalence of chronic HBV infection in the world has a wide range and varies 
between countries in the same continent, it can be classified into three areas: high 
endemicity (HBsAg > 8%), intermediate endemicity (HBsAg 2-8%), and low 
endemicity (HBsAg < 2%) (Hall, 1994; Mahoney, 1999).  
 
High endemicity areas (70 to 90% the lifetime risk of HBV infection and 8-20% 
become carrier) include Southeast Asia, Sub Saharan Africa, parts of the Middle East-
China, and some countries in Eastern Europe. The most infections occur at birth or in 
early childhood (WHO, 2002). 
 
However America, Western and Northern Europe, Canada, New Zeelanda and Australia 
are low endemicity areas (20% the lifetime risk of HBV infection and 2% become 




Intermediate areas are the Mediterranean countries, Japan, Central Asia, Middle East 
and Latin –South America (20-60 % the lifetime risk of HBV infection). And infection 
occur in all age groups (WHO, 2002). 
 
Palestine is considered as intermediate endemic area of HBV.  The HBV incidence rate 
in Palestine was 0.5 and 1.2 per 100,000 of population in West Bank  in the years 2009 
and 2010.The prevalence rate among hepatitis B carries in 2009 was 24 and 41.9 per 
100,000  of population  in Gaza strip and West bank respectively .The latest published 
reports on 2010 included 1373 carries in Palestine, and the prevalence rate was higher 
than 2009, it was found that 407 carriers in Gaza strip with prevalence rate 26.5, While 
966  carriers in West bank with prevalence rate 42.4 (Palestinian health information 
center, 2010). 
 
Figure(1.1): Annual Reported Incidence Rate of Hepatitis B Cases and Carrier, (per 
100,000), Palestine,2000-2010 (Palestinian health information center, 2010). 
    
On the regional level, in 2002 the prevalence among blood donors in Saudi Arabia was 
1.5% (El-Hazmi, 2004). In Egyptian blood donors in 2006 the prevalence was 4.3% 
(El-Gilany and El-Fedawy, 2006). HBV incidence rate in Jordan in 2005 was 0.583 
per 100,000, and it began to decrease annually,recent reports In 2010, showed that the 
incidence rate was 0.10 (Ministry of Health in Jordan). In Israel HBsAg prevalence 
rate of 5.8 - 0.5% (Hartman et al., 2002). 
   
There are many antiviral drugs that are used to cure HBV or to decrease its progression; 
in general classified into two categories of drugs; the immunomodulatory agent 
(interferon-alpha and peg-interferon) and nucleos(t)ide analogues (lamivudine, 
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entacavir, adefovir, telbivudine ) (WHO, 2002; Sablon and Shapiro, 2005; Block et 
al., 2007).  
 
The most common one in Gaza strip is lamivudine due to its good quality in HBV 
management and it is potent inhibitor of the viral reverse transcriptase with a sustained 
inhibition of viral replication.  
 
On the other hand, the major drawback of long term treatment with lamivudine results 
in amino acids variation in the virus and the emergence of drug resistance HBV mutant.  
The most common mutation occur in YMDD (tyrosine methionine aspartate aspartate) 
(Zollner et al., 2004) which is highly conserved catalytic polymerase/reverse 
transcriptase domain at position 204. The mutation (rtM204 V/I/S), is a substitution of 
methionine by valine or isoleucine (Bozdayi et al., 2004; Chien and Liaw, 2008), and 
serine (Lupo et al., 2009; Li et al., 2011) and it is called primary resistance. 
 
The other common mutation is (rtL 180M) with substitution of leucine by methionine in 
B domain of the polymerase gene (Wen and Li, 2007; Bottecchia et al., 2008).  
A secondary/compensatory mutation (Lamivudine: rtV173L) result in substitution of 
valine by leucine (Locarnini, 2006; Shaw et al., 2006).   
 
In Gaza Strip, lamivudine is used in the management of chronic hepatitis patients 
without any monitoring for the development of resistant mutants; hence, there is no 
available data on this issue. Data obtained from this research will shed light on the 
extent of the problem therefore, may be a foundation for a change in management 
protocols and policies. In addition, by detecting this mutation in chronic patients, 












1.2 Aim of the study 
The aim of this study is to detect lamivudine resistant Hepatitis B virus (HBV) by 
genotyping among chronic patients in Gaza strip.  
 
1.3 Objectives 
1.  To determine the prevalence of the most common mutations YIDD, YVDD 
among chronic HBV patient. 
2.  To examine the association between the existence of any mutation and a 
previous or current lamivudine therapy.  
3. To examine the association between mutant and viral response to lamivudine 
according to viral load. 
4.  To evaluate  liver function in relation to HBV resistance. 
 
1.4 Significance of this study 
Antiviral drug resistance is crucial in predicting the outcome of treatment. This 
study is important in the sense that it is the first to deal with hepatitis B drug 
resistance in Gaza strip. HBV is considered one of the most virulent viruses, easily 
transmitted leading to  cirrhosis, HCC and eventually lead to death, therefore, 
identification of the most common mutations in Gaza strip would be helpful in 

















2.1 Hepatitis B virus 
2.1.1Classification and structure of HBV 
Hepatitis B virus is a member of the Hepadnavirus group (hepatotropic DNA virus) of 
double-stranded DNA viruses (Baron, 1996; Kufe et al., 2003; Block et al., 2007). The 
hepatitis B virion (Dane particles) is about 40–42 nm particle in diameter, it is 
composed of the viral genome with viral polymerase by covalent bond.  
 
Viral genome enclosed within the icosahedral core called nucleocapsid (HBcAg)   
which is 27 nm in diameter assembled from 240 viral proteins and it is surrounded by 
an outer lipoprotein envelope that contains three related envelope of glycoprotein  or 
surface antigens (L:HBlAg, M:HBmAg, S: HBsAg) (Kufe et al., 2003; Block et al., 
2007; Riu, 2007 ). The most common surface proteins is HBsAg, It is 22-nm particles, 
sphere and tubular structures of the same diameter, and it is secreted by infected 




Figure (2.1): A schematic presentation of HBV Virion (Stefan et al., 2012)                
The genome is a relaxed–circular partially duplex DNA (rc DNA) of  3.2 kilobases in 
length, and a polymerase that is responsible for synthesis of viral DNA in infected cells.  
It consist of two linear strands of DNA held in a circular configuration by base pairing 
at the 5′ ends (Baron, 1996; Block et al., 2007; Poordad and Chee, 2010). One of the 
strands is incomplete only about 2/3 of the genome in length, noncoding shorter strand 
with positive sign, associated at 3' end with DNA polymerase need deoxynucleotide 
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triphosphate to complete the strand. The other strand is complete coding strand with 
negative sign (Mclachlan, 1991; Block et al., 2007).  
 
2.1.2 Organization of HBV genome  
The genome is 3020-3320 nucleotides long for the full length strand and 1700-2800 
nucleotides long for the short length strand (Kay and Zoulim, 2007).  The genome 
contains four partially overlapping conservative open reading frames (ORFs) to proceed 
protein synthesis, coding for the envelope proteins (pre-S/S: pre surface – surface) core 
(Pre-C /C:pre core-core), DNA polymerase (P gene), and transactivating X protein 
(Mclachlan, 1991; Kufe et al., 2003; Riu, 2007; Tian et al., 2007; Poordad and 
Chee, 2010). 
 
The transcription of these open reading frames is under the control
 
of four promoters 
(two surface promoters, one core promoter, and
 
one X promoter); and two enhancers 
(enhancer I and enhancer II), a poly-adenylation signal motif, and some signals for 
DNA replication (Tzang et al., 2001; Block et al., 2007).   
 
 
Figure (2.2): Genome organization, genome structure and transcription map of HBV. 
(A) Illustration of the HBV virion (1A), showing envelope, S, M, L, with their S, preS2 and 
preS1 domains in sub-boxes of size proportional to their polypeptide length. The HBV genome, 
contained within the capsid, is shown as a partly double stranded, incomplete circle, with the 
polymerase protein covalently attached to the “minus” strand. (B) The circular map of the HBV 
genome is shown, with nucleotides numbered from the single EcoR1 site (by convention) and 
transcripts and their polypeptide products indicated (Block et al., 2007).  
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The first open reading frame pre surface-surface encodes three forms of viral surface 
protein (HBL Ag large: L, HBm Ag middle: M, and HBs Ag small protein: S) that 
encode three start codons that are used for initiation of translation.  L protein is 
translated from 2.4Kb mRNA, the M and S proteins mainly from a set of 2.1Kb m 
RNAs, also S protein translated from 2.4 Kb m RNA (Kufe et al., 2003; Riu, 2007; 
Poordad and Chee, 2010). 
 
The envelope gene consists of three in phase ORF termed in 5- to 3- direction pre S1, 
pre S2 and S domain with stop codon. The S domain responsible for expression S 
protein that consists of two kinds of surface protein (HBs Ag): non glycosylated (p24) 
and glycosylated (gp27), together with middle proteins: M proteins (gp33 & gp36) 
which contain the pre S2 domain, a glycosylated 55 amino acid terminal. Virion surface 
has similar components, in addition large surface protein:L protein (p39, gp42) that 
contain both the pre-S1and S2 region (Baron, 1996). 
    
Figure (2.3): HBV envelope proteins and S-topology  
In panel A, the three products of the S-gene are represented as the large (L), the middle 
(M), and the small (S) envelope proteins. All of them share a common S-domain 
translated as the S-protein, whereas the M-protein contains an additional preS2-region, 
and the L-protein an additional preS1-domain. In panel B, the transmembrane regions of 
the S-envelope protein are depicted with numbers (I-V), which separate two hydrophilic 
domains. The first hydrophilic domain is a cytoplasmic-loop (internal loop), and the 
second is probably a luminal-domain, which contains the main antigenic region for the 
HBsAg (the a-determinant) and the glycosylation site (Glyc) (Block et al., 2007). 
 
The precore -core encodes hepatitis B core. The core promoter produces two 3.5-kb 
RNAs: the precore and pregenomic
 
RNAs. Precore RNA is responsible for the synthesis 
precore protein and secretion of HBeAg; a 16 KD fragment is a marker for active virus 
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proteins and serving as the template for reverse 
transcription(Tzang et al., 2001; Block et al., 2007).  
The core promoter
 
can be divided into two elements: the basal core promoter (BCP)
 
and 
the core upstream regulatory sequence (CURS) (Tzang et al., 2001). The P–ORF which 
extends along the whole HBV genome, which is the largest and overlaps the other three 
and code p protein of 94 KDa which contains 4 domains from amino to carboxy 
terminal the 5- terminal protein region, the  spacer region, reverse transcriptase / DNA 
polymerase domain and ribonuclease H (RNase H) (Stefan et al., 2012). So that this 
protein is a multifunctional with three enzymatic activities: it is a ribonucleic acid 
(RNA) dependent DNA polymerase( reverse transcriptase ), DNA polymerase  and 
RNAase H activity (Riu, 2007). P protein does also as a primer for the viral negative 
strand DNA synthesis, and RNA encapsdation (Riu, 2007; Stefan et al., 2012). 
 
The fourth ORF “X” is a 154 aa-sized (Kufe et al., 2003; Block et al., 2007) 
transcriptional transactivator code for polypeptide 17  KDa  (Baron, 1996; Block et al. , 
2007). The X protein named like this because of the function of it is not fully 
understood during viral infection .although most researchers focus on its potential 
carcinogenicity role ( Kufe et al., 2003; Block et al., 2007; Poordad and Chee, 2010). 
 
 
Figure (2.4): Transcript products of HBV with the proteins. 
Transcript products of HBV, with the proteins they specify (for mRNA) and encapsidation and 
replications (for pregenomes) CHO indicates N-linked glycosylation, and is positioned at the 
appropriate glycosylation sites. cccDNA, represented by the double lined circle on the left, is 
transcribed into at least 5 RNA gene products (Block et al., 2007). 
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2.1.3 Viral replication cycle 
The replication of HBV is "Retro virus like replication". It replicates by an intermediate 
reverse transcription step carried out by viral polymerase (Baron, 1996; Das et al., 
2001). Surface protein (Pre S1 domain) is necessary for attachment of HBV to 
hepatocytes; beginning the first point that it is the entry into the hepatocyte and capsid 
disassembly, so that viral DNA transport into nucleus, as a result the relaxed-circular 
DNA (rc DNA) is converted into covalently closed circular DNA (ccc DNA), using the 
negative strand of ccc DNA as transcriptional template, three subgenomic mRNA are 
formed; two surface mRNAs, precore and pregenomic RNAs, and an X mRNA 
(Tuttleman et al., 1986; Will et al., 1987; Block et al., 2007 ; Poordad and Chee, 
2010). 
 
Then after synthesis the RNAs are traveled to cytoplasm for translation, yields to DNA 
synthesis and assembly of viral particle occur, also expression of P protein that 
important for viral replication, whereas the core gene HBcAg, and surface protein 
required for the shell of the virus, as well as the X protein. Synthesis P protein is 
sufficient to stop further translation of pregenomic  Pg RNA (Block et al., 2007; Stefan 
et al., 2012). 
 
Next, nucleocapsid is assembled in the cytosol, at this moment genomic RNA is 
incorporated into the assembly of viral core. Once the viral RNA is encapsidated 
leading reverse transcriptase to begin, and allow DNA synthesis via its attachment to the 
5- end of its own template (Pollack and Ganem, 1994). 
 
The cccDNA genome is produced intracellularly and remains throughout the life of the 
chronically infected host, leading to  viral replication  after the initial infection 
(Poordad and Chee, 2010). 
 
The synthesis of two viral DNA strands is sequential. The first negative DNA strand is 
fully synthesized from encapsidated RNA, during or after the synthesis, RNA template 
were degraded using RNase H. Whereas the positive strand is synthesized (Summers 




Most cores, bud into intracellular membranes bearing the viral envelope proteins (L, M, 
S) and are then exported from the cell. HBs Ag play a negative feedback for HBV 
replication by inhibition cccDNA formation (Summers et al., 1990). 
 
Figure (2.5): HBV Replication cycle 
Major steps in the molecular biology of the HBV replication life cycle are shown, from 
attachment to translocation of the virion DNA to the nucleus, to conversion of entering 
viral DNA into cccDNA, followed by transcription of the cccDNA into the viral RNA 
gene products. Encapsidations in the cytoplasm, virion morphogenesis and secretion is 
also shown. Note, replicated progeny HBV DNA can return to the nucleus by way of an 
intracellular pathway, which may result in an “auto” amplification of cccDNA (Block et 
al., 2007). 
2.1.4 HBV Genotypes 
There are eight genotypes for HBV, based upon divergence of eight percent or more in 
the complete nucleotide sequence by insertion or deletion of nucleotides. They begin 
with genotype A and end with genotype H. They seem to be variants in geographical 
regions in their pathogenicity and epidemiology (Lai et al., 2003b; Payungporna et al., 
2004; Niesters et al., 2005; Sablon and Shapiro, 2005; Block et al., 2007; Masaadeh 
et al., 2008; Clements et al., 2010). 
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Genotype A is predominant in Northen Europe, North and Central Africa, and India. 
Whereas genotype B and C are found in Asian Pacific area. While D genotype in 
Southern Europe, Middle East and India. While E genotype found in West Africa and F 
genotype is predominant in Central and South America. G genotype is predominant in 
United State Kingdome and America. The final genotype H was found in Central 
America   (Niesters et al., 2005; Sablon and Shapiro, 2005; Sherman et al., 2007; 
Damerow et al., 2010).  
 
 
Figure (2.6) :Worldwide distribution patterns of HBV genotypes and subgenotypes 
Regions with high, intermediate and low endemicity are shown by grey, light grey and 
white shades respectively (Datta, 2008). 
 
2.1.5 Clinical Features 
HBV causes both acute and chronic hepatitis. The incubation period range from 45-160 
days (McMahon et al., 1985). The onset of acute disease is insidious. When present, 
clinical symptoms can be observed like dark urine, jaundice, anorexia, fever, malaise, 
nausea, vomiting and abdominal pain. Also other extra hepatic manifestation of disease 
like skin rashes and arthralgias (Dienstag, 1981; Fung and Lok, 2004; Sablon and 




The case fatality rate after acute hepatitis B is 0.5-1%. In adult with normal immune 
status, almost over 94 to 98% recover completely from acquired HBV infection 
(McMahon et al., 1985; Shepard et al., 2006). On the other hand, about 15-25 % of 
chronic HBV die prematurely from cirrhosis or hepatocellular carcinoma (Beasley et 
al., 1981; McMahon et al., 1990). 
 
 Figure (2.7): Evolution of HBV markers in acute and chronic infection (Sablon and 
Shapiro, 2005). 
 
2.1.6 Diagnostic tests 
Due to the similarity in HBV symptoms with other forms of viral hepatitis, the most 
common test for diagnosis of HBV infection are mentioned in the following section. 
 
2.1.6.1 Antigen detection 
HBsAg 
In recent infected patient, the most common serologic hallmark test is HBsAg, It is 
present in serum after six weeks or 30-60 days after infection with HBV. The 
disappearance of HBsAg is followed by the appearance of hepatitis B surface antibody 
(anti-HBs). (Hussain and Lok, 2002; Dore et al., 2006; Shepard et al., 2006; Riu, 
2007; Stefan et al., 2012).  
Anti HBc 
Hepatitis B core antigen (HBcAg) is an intracellular antigen expressed in hepatocytes. 
As a result not detectable in serum. On the other hand Anti-HBc can be detected there. 
Anti HBc develops in all HBV infections, appearing at onset of symptoms and 
abnormalities in acute patient liver test. Also it was found that the presence of 
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immunoglobulin M (IgM) class of anti HBc for six month in acute infection (Hussain 
and Lok , 2002; Stefan et al., 2012). 
 
HBeAg 
The third antigen HBeAg can be observed in both acute and chronic HBV infection. It is 
coincide with viral replication and high level of virus and higher rates of transmission of 
HBV infection.Wherease Anti HBe correlate with lower level of virus (Dienstag et al., 
1999). 
 






 IgM IgG  
+ + - - - - Incubation period 
+ + - + + - Acute hepatitis B or 
persistent carrier state 
+ + - - + - persistent carrier state 
+ - + +/- + - persistent carrier state 
- - + +/- + + Convalescence 
- - - - + + Recovery 
- - - + - - Infection with hepatitis 
B virus without 
detectable HBsAg 
- - - - + - Recovery with loss of 
detectable anti-HBs 
- - - - - + Immunization without 
infection, repeated 
exposure to antigen 
without infection, or 
recovery from infection 







2.1.6.2 HBV DNA Detection 
 
HBV DNA is detectable in serum of acute and chronic patients. The major clinical 





 IU /ml is at high risk of progression to advanced liver disease (Sablon 
and Shapiro, 2005; Dore et al., 2006; Shepard  et al., 2006). Hence, it is direct marker 
and gold standard for HBV viral replication. On the other hand it gives wide variation in 
test sensitivities and relatively slower to detect drug resistance (Sablon and Shapiro, 
2005).  
Determination HBV DNA level in serum is an effective tool to monitor the fidelity and 
response of treatment (Payungporna et al., 2004). Qualitative or quantitative tests 
techniques are used for determination HBV DNA level (Dienstag et al., 1999; Sablon 
and Shapiro, 2005; Stefan et al., 2012). Now the most HBV DNA assays use real-time 
PCR techniques, due to high sensitivity; the lower limit of detection of around 20 
IU/mL and a range of linearity up to 8 log10 IU/mL (Stefan et al., 2012). 
 
2.1.7 Vaccination 
In 1970s began the evaluation of first hepatitis B vaccines, but the first licensed HBV 
vaccine where in 1982 (Mahoney, 1999). The first hepatitis B vaccines were plasma 
derived and consist of purified HBsAg. The most widely used vaccines in the world are 
plasma derived vaccine  and recombinant vaccine (Baron, 1996 ; Mast et al., 2005; 
Block et al., 2007). 
 
Hepatitis B vaccines are given in a three dose series. The recommended dosage of 
vaccine differs depending on the age of the recipient and type of vaccine (Mast et al., 
2005). About 80 to 100 percent of vaccinated person were protected from HBV 
infection (Andre, 1990; Riu, 2007). It is very useful in postexposure 
immunoprophylaxis to prevent perinatal transmission (Greenberg, 1993).  However 
vaccination can cause emergence of HBV genomes with specific mutations, designated 






2.2 HBV drugs  
Treatment goals are to interrupt HBV further transmission, and reduce the complication 
of HBV infection such as liver injury or damage and hepatocellular carcinoma (HCC) 
and by acting on inhibition and elimination virus replication. As a result, for using 
HBVdrugs a reduction in serum HBV DNA occurred less than 10 
5
 IU/ ml (WHO, 
2002; Sablon and Shapiro, 2005; Block et al., 2007). 
 
The U.S food and drug administration (FDA)  approved two type of drugs for the 
treatment of chronic HBV infection; the first is immunomodulatory agent (interferon-
alpha and peg-interferon) that enhance the attack of virus by the immune system, the 
second is four nucleos(t)ide analogues, that inhibit HBV reverse transcriptase activity 
causes impairment of replication of the virus, such as  lamivudine, entacavir, adefovir, 
telbivudine (WHO, 2002; Sablon and Shapiro, 2005; Block et al., 2007).  
  
2.2.1 HBV Immunomodulatory Agent (Interferon)  
Interferon (IFN) was used since the mid-1990s  (Chien and Liaw, 2008), in order to 
inhibit HBV replication by activation of viral ribonuclease so that it is antiviral, also has 
a role as immunomodulatory effect via activating macrophages, natural killer cells and 
cytotoxic T cell. Unfortunately its cost high (Dienstag et al., 1999; Riu, 2007; Li et al., 
2011), injection dependent and lead to adverse effect like fatigue, leucopoenia, hair loss 
and anorexia (Dienstag et al., 1999; Fung and Lok, 2004; Sablon and Shapiro, 2005; 
Sherman et al., 2007; Li et al., 2011 ). 
  
2.2.2 HBV Nucleos(t)ide Analogues  
The frequently used antiviral drugs may be classified into:  
i) L-Nucleoside Group (lamivudine, emtricitabine, telbivudine, clevudine) 
ii) Acyclic Phosphonate Group (adefovir, tenofovir)  
iii) Deoxyguanosine analogs; cylopentene/cyclopentane Group (entecavir/abacavir). 
(Locarnini, 2006; Shaw et al, 2006; Poordad and Chee, 2010).  
 
Lamivudine was the first approved nucleoside medication for the treatment of chronic 
HBV by Food and Drug Administration (FDA) in 1998 (Dore et al., 2006; Tsubota, 
2006; Tunçbilek et al., 2008; Hige et al., 2010; Li et al., 2011); due to its good effect 
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in improving liver histology, reducing disease activity, and delaying clinical progression 
via inhibition of viral replication (Tunçbilek et al., 2008; Feng et al., 2011).  
 
Entecavir inhibits HBV replication at three different steps; the priming of HBV DNA 
polymerase, the reverse transcription of the negative strand HBV DNA from the 
pregenomic RNA, and the synthesis of the positive strand HBV DNA (Xiong et al., 
1998; Colonno et al., 2001; Fung and Lok, 2004;Sherman et al., 2007; Poordad and 
Chee, 2010).  
 
Entecavir and tenofovir have good quality and little or no resistance in treatment patient 
in the first years (Lai et al., 2003b). Studies showed that entecavir is more potent than 
lamivudine and Adefovir. It is effective against lamivudine-resistant HBV mutants 
although the activity is lower compared to wild-type HBV (Xiong et al., 1998). 
 
While tenofovir is very effective in inhibiting the replication of YMDD mutant (Ying et 
al., 2000; Fung and Lok, 2004; Yuen et al., 2009). And it's more efficacious in long 
term than adefovir in lamivudine resistant patients (Shaw et al., 2006). 
 
Adefovir dipivoxil is a purine nucleotide analogue; the standard dose is 10 mg/day. 
Adefovir is not a highly potent agent (Sherman et al., 2007). It can inhibit both the 
reverse transcriptase and DNA polymerase activity and is incorporated into HBV DNA 
causing chain termination (Lok and McMahon, 2001). Clinical studies showed that 
adefovir is effective in suppressing wild type as well as lamivudine resistant HBV (Lok 
and McMahon, 2001; Shaw et al., 2006). 
 
New analogues are under development or in advanced clinical trials such as 
emtricitabine, telbivudine and clevudine (Block et al., 2007; Chien and Liaw, 2008; Li 
et al., 2011). Telbivudine is more potent than lamivudine in suppressing HBV 
replication (Rosina et al., 1991). It has proven results on patients with elevated viral 







Table (2.2): Comparison of Approved Treatments of Chronic Hepatitis B (Lok and 
McMahon, 2001; Stefan et al., 2012)  




























Duration 4-6 month 4-6month 48weeks Long-term Long-term Long-term Long-term 
Side 
 effect 






 year 1 %20 ـــــــــــ





>25% up to 
Year2 
Cost High Low Medium High Medium 
Route Subcutaneous Oral Oral Oral Oral 
 
2.3 Drug resistance 
Viral replication is estimated to be 10
11
 virons per day (Feng et al., 2011), with an error 
rate of 10
-5
 (Gunther et al., 1999). Most of which do not have adequate replication 
fitness to be detectable with standard commercially available assays. The high 
frequency of variants is in large because of the lacking of proof reading activity of P 
protein during reverse transcription and DNA synthesis (Gupta et al., 2006; Riu, 2007; 
Poordad and Chee, 2010). And the large replication space in the liver. This allows the 
variant type to escape from immune suppression as a result formation drug resistance 
(Locarnini et al., 2004). 
 
Drug resistance due to viral mutations may be evident from increasing DNA level, 
where viral load is (≥1.0 log IU/ml) and determination of genotypic markers of drug-
resistance (Shaw et al., 2006).  There are many factors associated with emergence of 
drug resistance like drug properties, and treatment regimens (Yuen et al., 2009). 
 
Drug resistance can be identified by genotyping and/or phenotyping terms. Genetic 
resistance refers to viral population with amino acid changes in polymerase region that 
are associated with some degree to antiviral agent and decrease the efficacy of the 
antiviral agent (Sherman et al., 2007; Poordad and Chee, 2010). It is concerned with 
analysis viral genome sequence, in order to determine mutation in the viral polymerase 
gene after treatment using DNA sequencing or hybridization techniques (RT-PCR or 
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line probe assay), PCR and restriction fragment length polymorphism (RFLP) analyses 
(Shaw et al., 2006). 
 
Phenotyping relies on decreasing the suppression of HBV replication in the presence of 
specific mutation in the polymerase gene  and characterizing high viral DNA  level by 
cell culture and other techniques in order to be quantified (Shaw et al., 2006; Sherman 
et al., 2007; Poordad and Chee, 2010). 
  
Table (2.3): Genotypic and phenotypic assays (Poordad and Chee, 2010) 
  Advantages Disadvantages 
Genotypic assays 
Direct PCR sequencing Thorough identification of 
all mutations 
Poor sensitivity (∼ 20%) 
Restriction fragment-
length polymorphism 
Sensitive to∼ 5% Requires separate 
endonuclease reactions 
for each mutation 




Requires specific probe 
for every mutation 
DNA microchip Able to detect new 
mutations 
Expensive 
Not widely available 
Mass spectrometric 
analysis 











Good for single mutations 
Not applicable for 
multiple or complex 
mutations 
Whole HBV genome 
amplification/cloning and 
transfection 
Whole HBV genome 
variability 
Cross-resistance testing 
Requires cloning step 
Cell transduction using 
Baculovirus vector 




 Permanent cell lines with 












Unfortunately, resistance to nucleos(t)ide analogs was noted with many drugs, 
especially lamivudine. Adefovir resistance was more slowly than lamivudine resistance, 
approximately 2.5% over four years. As well as the resistance were found also in 
tenofovir, telbivudine, and entacavir (Shaw et al., 2006; Sherman et al., 2007).  












Figure (2.8): Genotypic resistance through 5 years for HBV nucleos(t)ide analogs in 
treatment naïve patients( Poordad and Chee, 2010). 
 
2.3.1 Lamivudine Therapy: 
 
 
Lamivudine the negative enantiomer of deoxycytidive 3TC (2 deoxy_3_ thiacytidine) is 
an oral cytosine analogue. It was the second approved medication for the treatment of 
chronic HBV by Food and Drug Administration (FDA) in 1998 (Dore et al., 2006; 
Tsubota, 2006; Tunçbilek et al., 2008; Hige et al., 2010; Li et al., 2011;). The brand 
name of lamivudine is EPIVIR (also known as 3TC), It is one pill per day regimen (100 
mg), characterized by good clinical tolerability with few adverse effects and affordable 
cost (Sablon and Shapiro, 2005; Sherman et al., 2007). So that it is safe and effective 




Lamivudine improves liver histology, reduce disease activity, and delays clinical 
progression (Tunçbilek et al., 2008; Feng et al., 2011), and inhibit viral replication by 
suppressing HBV DNA minus strand elongation due to competition with the 
polymerase substrate dCTP  for incorporation into the growing viral DNA chain. Also it 
plays a role in chain terminator through its combination with the nascent DNA strand 
(Lok and McMahon, 2001; Tunçbilek et al., 2008).  
 
Lamivudine reduce serum HBV DNA level  as a result of interruption of  both strands 
of  HBV DNA synthesis and suppressing RNA-DNA dependent DNA polymerase 
(Stefan et al., 2012), and keep ALT (Alanine Amino Transferase) at normal range (Lai 
et al., 2003b; Li et al., 2005).  
 
2.3. 2 Lamivudine mutations 
Unfortunately, resistance to nuclos(t)ide analogs was noted with lamivudine. The major 
drawback of  taking lamivudine for at least one year leads to amino acids variation 
(single point mutation ) in the reverse transcriptase domain  of the viral polymerase 
gene, with most substitutions occurring in B, C, and D domain (Fung and Lok, 2004 ; 
Poordad and Chee, 2010; Li et al., 2011). 
 
These mutations lead to elevated serum HBV viral load, interrupting the liver enzymes 
like ALT, elevated histological activity index, high body mass index, slow virological 
response. Viral load is the amount of virus in body fluid in given volume of blood, and 
is used to investigate the efficiency of the drug (Zollner et al., 2004; Sherman et al., 
2007; Chien and Liaw, 2008 ). 
 
Results of studies indicate that the lamivudine resistance rate is increased from 14-36 % 
after one year; in  the next year it is increased to 38%, and in the following two years it 
reaches 49-50% and 66-70% respectively (Zollner et al., 2004; Sablon and Shapiro, 
2005; Gupta et al., 2006; Mohanty et al., 2006; Tsubota, 2006; Stefan et al., 2012  ). 
 
However, lamivudine still exert its therapeutic effect in combination regimens or in 
mild chronic hepatitis B patients with low level of HBV DNA (less than 10
5
 IU/ml) 
(Sherman et al., 2007).  
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2.3.2.1. HBV polymerase mutations 
The HBV polymerase gene is the target for nucleoside and nucleotide analogs. It is  344 
amino acids in length. The enzyme has four functional domains (terminal protein, 
spacer, Pol/rt, and RNaseH), with seven catalytic subdomains (A–G) in the Pol/rt 
region. Antiviral drug-resistant strains have signature mutations in the reverse 
transcriptase domains of the viral polymerase gene, with most substitutions occurring in 
domains B, C, and D. Resistance mutations alter the interaction between HBV 
polymerase and drug (Poordad and Chee, 2010; Strasfeld and Chou, 2011). 
 
There are eight codons in the polymerase of HBV that are associated with primary drug 
resistance (codon 169, 180, 181, 184, 202, 204, 207,213, 236, and 250) (Poordad and 
Chee, 2010). Also other most common mutations located in codon position 173, 213 
and 207 (Li et al., 2011). The reported annual incidence of resistance to lamivudine is 














Figure (2.9): HBV Polymerase Nucleoside Analogue Resistance Mutations (Strasfeld 




The most common mutations associated with lamivudine occur in the YMDD (tyrosine 
methionine aspartate aspartate) motif in the C domain of the polymerase gene which is 
highly conserved catalytic polymerase/reverse transcriptase domain at position 204 
(Zollner et al., 2004; Strasfeld and Chou, 2011). Seven variants were made by 
subsituation the methionine (M) of the YMDD motif with isoleucine (I), valine (V), 
alanine (A), leucine (L), lysine (K), arginine (R),and threonine (T).These produced by 
one point mutation into codon ATG coding methionine (Strasfeld and Chou, 2011). 
 
In the C domain of HBV polymerase (rtM 204 V/I/S). The methionine at codon 204 is 
replaced by an isoleucine, which is the most dominant one (Pas et al., 2002; Poordad 
and Chee, 2010) (rt M204 I), or by valine ( rt M204 V ) and in most cases accompanied  
by rt M 180 (Pas et al., 2002; Chien and Liaw, 2008; Poordad and Chee, 2010; Feng 
et al., 2011 )  and  by serine (rt M 204 S ) (Bozdayi et al., 2004).  
 
There are three commonly sequences can code for YIDD: ATC, ATT, and ATA; where 
G is converted into C, T and A code for isoleucine. The other mutation was YVDD in 
which the common codon sequence GTG, GTT codes valine (Ono-Nita et al., 1999; 
Wightman et al., 2004). While in YSDD mutation ATG converted to AGT leading to 
amino acid changes in 195
th
  codon of surface gene from tryptophan to valine (Bozdayi 
et al., 2004). 
 
Rt M 204 I and rt L180M / M204 V are the two most commonly mutant (Lai et al., 
2003a; Poordad and Chee, 2010). In addition to the emergence of the YMDD 
mutations, (rtL180M and rtV173L) mutations in the B domain of HBV polymerase are 
frequently observed (Bottecchia et al., 2008; Poordad and Chee, 2010). Other 
lamivudine mutations were rtL80V/I, rtA181 T/V, rt I 169T and rtT184 S/G (Shaw et 









Figure (2.10): Mutations within the pol gene can result in changes within the envelope 
protein. The polypeptide specified by the pol (polymerase) and env (envelope) genes are 
expanded as horizontal boxes. The amino acid sequence of the polymerase between 
amino acids 163 and 210 is the region that contains amino acids that, when mutated, can 
confer resistance to some polymerase inhibitors. The YMDD amino acid motif 
(underlined), for example, when mutated (as shown) confers resistance to lamivudine 
and is provided with the amino acid transition indicated. Since the open reading frames 
for pol and env overlap, (amino acid 204 of the rt (reverse transcriptase) roughly 
correspond to amino acid 195/6 of the envelope protein, as indicated) a change in this 
motif will change the amino acids specified by the env open reading frame, and this is 




2.4 Lamivudine resistance around the world 
Five related studies were carried in different parts of China in order to determine the 
prevalence of lamivudine resistance among chronic hepatitis B patients, who received 
lamivudine; Two of them were the  most important,  the first investigation, one hundred 
and nine patients with HBV YMDD mutation were enrolled; 45 patients had 
rtL180M/M204V mutation (41.28%), where 28 patients had rtL180M/M204I mutation 
(25.70%), 36 patients had rtM204I mutation (33.02%), and 6 patients had rtL180M 
mutation (18.75%) (Li et al., 2005).  
 
While the second study was two related studies were carried about lamivudine 
resistance; the first study showed that the prevalence among Chinese patients 
were 65.7 % YMDD, 18% YIDD and %16 YVDD. In the second study were 
49% YMDD, 36% YIDD and 1 % YVDD (Shi et al., 2006). 
 
Two studies were done in Japan; the first 13 /42 (30.95%) patients harbored HBV with 
LMV resistant, they were divided into three categories: 54 % had YIDD (7/13), 31% 
had YIDD+ L180M (4/13), and 15% had YVDD+ L180M (2/13) (Kumashiro et al., 
2003). Another study reported that LMV resistant five patients from twenty, they were 
four patients had YIDD (25%) and one patient had YVDD (5%) (Chayama et al., 
1998). 
 
Romas et al., (2007) during their investigation of eighty-one of HBV coinfected with 
HIV patients, they found that the dual L180M & M204V/I mutant was the predominant 
resistance pattern, although a triple rt173V, 180M and YVDD pattern was found 1 
patients in Madrid, Spain.  
 
While in Turkey one tenth of chronic hepatitis B virus patient can be have lamivudine 
resistance, 77 chronic HBV patients were tested for lamivudine resistant, the result was 
6 patients with LMV mutations (7.79%), 4 patients of them with YVDD (5.19%) and 
the other 2 patients had YIDD mutation (2.59%) (Tunçbilek et al., 2008). This also 
correlates with Italian investigation, that approximately the prevalence of YVDD is 
54.2% (13/24) twice YIDD is 29.1% (7/24) the mutation, however the prevalence of 




In Netherland, twenty-two chronically infected patients were selected, the result was 
about 13 patients had lamivudine resistance (59%), five of them had rtM204V mixed 
with rtM204I (38.46%), the others eight patients showed predominantly rtM204I  
(61.5%) and in three had rtM204V could be identified (Pas et al., 2002).  
 
Forty–one patients  in Germany, carrying LMV resistant were followed  for one year 
during continuous LMV  therapy, then they became thirty four; thirteen patients of them  
had rtM204I (38%) , and the other twenty-one patient had rtM204V mutation (62%) 
(Zollner et al., 2004). While 20 Canadian patients with clinical manifestation of LMV 
resistance were studied, 7 patients had YVDD+L180M (35%), and 6 patients had YIDD 
(30%) (Allen et al., 1998).  
 
In Brazil, lamivudine resistance mutations were 67% among HBV DNA positive 
samples  (Niesters et al., 2005), this coincide with another study that showed the 
lamivudine resistance  prevalence 62% (20/32 patients), fifteen patients of them had 
double mutation L180M/M204V, and only 2 patient had triple mutation 
rt173V/180M/204V (Bottecchia et al., 2008).  
 
The most relevant country for us that studied the lamivudine resistant was Jordan, 107 
patients were included, and only 20 cases were tested for lamivudine resistant mutation 
(18.69%). Six mutations were detected on 5/16 patients with a history of lamivudine 
treatment (31%), the mutation were (4 YIDD = 25%, 1 YVDD = 6.25%, and 1 L180M= 
6.25%). Also double mutation was found in one patients (YIDD and L180M), and one 












MATERIALS AND METHODS 
 
3.1 Study Population  
Two governmental centers of Gaza Strip were included in this study. The first center at 
Al-Shifa hospital in the center of Gaza city serving patients from Gaza,  North and 
Middle governorates of Gaza Strip; the second at European hospital in Khan Yunis city 
serving patients from Khan Yunis and its neighboring camps; and patients from Rafah . 
 
The patients from both centers were referred either to the Central Laboratory of the 
Ministry of health or Balsam Medical Laboratory at Sheikh Radwan in Gaza for viral 
load determination between October 2008 and July 2011. The total number of patients 
was one hundred (72 males and 28 females). 
 
3.2 Setting  
Nucleic acid extraction and viral load determination were carried out at the molecular 
biology laboratories of Al Remal Clinic and Balsam Laboratory, and lamivudine 
resistance real-time PCR experiments were carried out at the molecular biology 
laboratory of the Islamic University of Gaza. Liver function tests were carried out at 
governmental centers laboratories (Al-Shifa hospital and European hospital).  
 
3.3 Questionnaire and Data Collection 
Personal and clinical data were collected either from the patients' medical records at Al 
Shifa hospital, European hospital, and Al Remal Clinic, and by a close ended and 
multiple choice based questionnaire in Arabic. The collected data included age, sex, and 
residency, history of infection, type of treatment, the duration of treatment and the place 
of treatment (Refer to appendix A for the complete questionnaire). 
  
3.4 Ethical Considerations 
The necessary permissions for conducting the study were requested from and approved 
by the Islamic university, the committee of Helsinki (declaration of Helsinki the most 
widely accepted guideline and medical research involving human subject refer to 
appendix B) and the Palestinian ministry of health MOH (Appendix C). 
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Verbal consent was obtained from all patients before any specimen collection and its 
possible outcomes were explained to all subjects. All personal information of the study 
subjects and result were dealt with confidentially. 
  
3.5 Reagents and Equipment  
3.5.1 Reagents  
The reagents consumed in the study are listed in table (3.1).  
Table (3.1): Reagents consumed during the study  
 
3.5.2 Primers and probes  
The primers and probes used for lamivudine resistance determination listed in table (3.2) 
Table (3.2): Primers  and probes sequences used for lamivudine resistant detection 
Primers/p
robe 
















































AGA-  MGB-3′, 
 
R refer to G/A 
 
Chemicals and reagents 
    Mag Max
TM
   Viral RNA Isolation Kit (Ambion), Applied Biosystems, USA 
    TaqMan®  Universal PCR Master Mix), Applied Biosystems, USA 
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3.5.3 Equipment  
The equipments used in the study are listed in table (3.3).  
Table (3.3): Equipment used during the study 
Manufacturer   Instruments  
Applied Biosystems, USA  Real time PCR instrument  
Sanyo, UK   Microcentritfuge  
Applied Biosystems, Singapor 





Figure (3.1): Photograph of 
Microcentritfuge. 
Figure (3.2): Photograph of Real time 
PCR instrument. 
 
3.6 Methods  
3.6.1 Patients and Samples Collection 
During the period from October, 2008 to July 2011, blood samples were collected from 
100 lamivudine-treated patients with chronic hepatitis B virus infection.  Seventy six 
samples were obtained from patients at Balsam Medical Laboratory and 24 from Al 
Remal Clinic.  
Blood samples were collected from each patient, in a plain tube or EDTA whole blood. 
Serum or plasma were separated  and  frozen at -70°C in a sterile, DNAse, RNAse free 
tightly capped tube until used for viral load by real-time PCR or the COBAS 
AMPLICOR system (Roche, Germany). Patients with viral load above 4500 IU/ml were 
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selected (54 patients) for analysis for Lamivudine resistance.
  
Six patients were from Al 
Remal Clinic and 48 from Balsam medical laboratory. They were 13 female and 51 
males with mean age 32.35 years. 
 
3.6.2  Biochemistry (Liver function tests ) 
ALT and AST levels were obtained from the patients records in Al-Shifa and European 
Gaza hospitals.The normal ranges for ALT and AST were from 0 to 40 IU /ml and 0 to 
37 IU /ml respectively. 
 
3.6.3 Virology 
3.6.3.1 Viral DNA Extraction 
The Mag Max Viral RNA isolation kit (Applied Biosystems, USA) was used to isolate 
the viral DNA according to the manufacturer instruction. The sample was disrupted in a 
guanidinium thiocyanate based solution that rapidly releases viral RNA and DNA while 
simultaneously inactivating nucleases in the sample matrix.  
 
Paramagnetic beads with a nucleic acid binding surface were then added to the sample 
to bind nucleic acids. The beads / nucleic acids were captured on magnets and proteins 
and other contaminants were washed away. The beads then were washed again to 
remove residual binding solution. Nucleic acids were eluted in a small volume of the 
provided elution buffer. 
 
 3.6.3.2 Real Time PCR determination for viral load  
Quantitation of the viral DNA was performed using the Cobas Amplicore system 
(Roche, Germany) according to the manufacturer recommendation; or using in house 
designed Real-time standard curve method. Amplification was performed in a 50-ml 
reaction mixtures containing 1X TaqMan Universal Master Mix (Applied Biosystems, 
USA), 0.72 μ M of a specific 6-FAM labeled probe and 2 μM of each of the forward 
primer and the reverse primer and 5 ml of isolated DNA. 
 
Amplification and detection were performed with an ABI Step One system (Applied 
Biosystems, USA). After incubation for 2 min at 50°C, which enables uracil N9-
glycosylase present in the Universal Master Mix to inactivate possible contaminating 
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amplicons, incubation for 10 min at 95°C allowed AmpliTaq Gold polymerase to 
activate and inactivate the uracil N9-glycosylase.  
The PCR cycling program consisted of 40 two-step cycles of 15 seconds at 95°C and 
one minute at 60°C. 
 
3.6.3.3 Real Time PCR genotyping   
The reactions were carried out using Taq Man universal  master mix (Applied 
Biosystems, USA) on the StepOne Real-Time PCR System (Applied Biosystems, 
USA). 
 
The amplification was performed in a 15-μl reaction mixture in three parallel tubes each 
containing 2 pmoles of each primer and the probe in the case of YMDD and YVDD; 
and 1 pmole of each primer and probe in the case of YIDD. The mixture also contained 
1X of the provided Taq Man universal master mixture and 5 μl of extracted DNA.  
 
The reaction cycling conditions consisted of denaturation for 10 min at 95°C, followed by 
43 cycles at 95°C for 15 seconds and 60°C for 1 min.  
 
3.7 Data Analysis 
  
Positive samples were calculated by interpolation of threshold cycle (Ct) below 40, by 
using StepOne Software 2.0 (Applied Biosystems). 
 
The data (from patients samples and questionnaire) was summarized, tabulated and 














This study focuses on determining the most widely mutations in HBV DNA polymerase 
due to long term use of  lamivudine therapy among HBV patients, and detecting the 
main risk factors associated with these mutations.   
4.1 Patients Description 
The study was conducted on HBV patients attending medical centers in Gaza Strip; the 
Balsam medical laboratory at Sheikh Radwan in Gaza and Al Remal Clinic in Gaza 
Strip. 
As inclusion criteria, the study accepted only 100 mg lamivudine-treated patients who 
have viral load above 4500
 
(IU/ml).  During the period from October 2008 to July 2011.  
 
4.1.1 Patients Distributions 
The study was conducted on 54 patients attending the Balsam medical laboratory at 
Sheikh Radwan and Al Remal Clinic in Gaza Strip. We divided them into two groups 
according to the hospitals, at which they are followed up .Thirty-one patients were from 
Al-Shifa hospital in the center of Gaza City, and twenty- three patients were from The 
European Gaza hospital in Khan Younis (Figure 4.1). 
 
 











 age ranged between 4 to 71 years; 10 patients were less than 20 years old, 
33 patients between 20 and 45 years; 11 patients were over 45 years. The mean age for 
all patients was 32.35   years with standard deviation (SD) 14.31 years(Figure 4.2). 
 
Figure (4.2): Distribution of patients according to their age. 
 
4.1.3 Patients Gender 
The 54 patients tested, were 41 males and 13 females. 
For males patients the mean age were 46.85 years, while females patients mean age 
were 30 years (Figure 4.3). 
 
 
Figure (4.3): Distribution of patients' gender 
 
4.1.4 Patients Residence Distribution 
Patients were from four regions of Gaza Strip. Twenty one patients were from Gaza 
governorate, 8 patients were from northen governorate, 6 patients from Khan Yunis 
governorate, and 19 patients were from the Rafah governorate( Figure 4.4). 
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Figure (4.4): Distribution of patients' residence. 
 
4.1.5 Patients Viral Load Level 
The HBV viral load level in patients serum was classified into two categories; the first 
24 patients were below 10 
7  
IU/ml, and the second above 10 
7




Figure (4.5): Distribution of patients' viral load. 
 
4.1.6 Patient Liver Function test (ALT, AST) Level 
The patients were divided into two groups based on each of their liver function tests 
(ALT and AST),  compared to the normal value. 
 
First, 11 patients had ALT levels below and 28 patients above 40IU/ml. Second 16 





Figure (4.6): Distribution of patient’s ALT and AST. 
 
4.1.7 Lamivudine intake duration 
 According to lamivudine intake duration mainly classified into two categories. 
First less than one year; they were 18 patients. Whereas 26 patients were receiving this 
drug more than one year (Figure 4.7). 
 
Figure (4.7): Distribution of patients according to lamivudine intake duration. 
 
4.1.8 The prevalence of lamivudine resistance 
First we look for threshold line which is the level of detection or the point of which a 
reaction reaches a fluorescent intensity above background. Next we concerned with the 
threshold cycle (Ct), it is the cycle at which a significant increase in fluorescence 
occurs, and reaches the threshold level. Positive samples were calculated by 
interpolation of threshold cycle (Ct) below 40, by using StepOne Software 2.0 (Applied 




4.1.8.1 YMDD (Tyrosine methionine aspartate aspartate) 
Determination the wild type YMDD in patient, it was found in most of patients, 39 
patients were positive and the other 15 patients were negative (Figure 4.7). 
 
4.1.8.2 YVDD (Tyrosine valine aspartate aspartate) 
Determination the first resistant type YVDD in patient, it was found only in four 
patients, and the other 50 patients were negative (Figure 4.7). 
 
4.1.8.3 YIDD (Tyrosine isoleucine aspartate aspartate) 
Determination the resistant type YIDD in patients, it was found in 31 patients, and the 
other 23 were negative. Thus the prevalence was 46 % (Figure 4.7). 
 
In other words the prevalence was divided in this study into five categories; the first 
category is the wild type (YMDD) it was found alone in 15 patients from 46 patients 
(32.6%), the second YMDD mixed with YIDD in 21 patients (41.3%), the third was 
YIDD alone it found in 6 patients (13%), the fourth YIDD + YVDD only one patient 
(2.2%), the fifth was YMDD + YIDD + YVDD in (10.9%). Eight samples were not 
typable in the study, probably, as a result of the presence of other mutations in the PCR 









4.2 Factors associated with lamivudine resistance  
4.2.1 Lamivudine resistance genotypes and the patients’ age. 
The mean age for the five groups: YMDD (Wild type), YIDD, both YIDD/YVDD, 
YIDD/YMDD, and YMDD/YIDD/ YVDD ranged from 27 to 37 years (Table 4.1).No 
statistically significant difference between the mean age was obtained, since p value is 
(0.687) . 
Table(4.1): Comparison between the mean age of the different Lamivudine 
resistance genotypes. 
Genotypes 
No. Mean Std. Deviation P-value 
YMDD 15 36.60 15.715 0.687 
YIDD 6 28.00 9.338 
YIDD /YVDD 1 34.00 . 
YMDD / YIDD 19 33.26 17.130 
YMDD / YIDD / 
YVDD 
5 26.60 13.975 
Total 46 32.96 15.281 
 
By comparing the mean age of the wild type from one side and the other resistant 
genotype from the other side, no statistically significant difference was obtained (P-
value = 0.11) (Table 4.2). 
 
Table(4.2): Comparison between the mean age of YMDD and all different 




Genotypes No. Mean Std. Deviation P-value 
YMDD 15 38.13 16.643 0.111 
Other 31 30.45 14.182 







4.2.2  Lamivudine resistance genotypes and patients' sex 
The majority of the patients studied were males (78.3 %). Similarly, in all of the 
genotype groups males were more than females and thus the distribution of the detected 
genotypes was no statistically significant either when considered separately (P-value = 
0.318) or collectively (P-value = 0.336) (Table 4.3).  
Table(4.3): distribution of Lamivudine resistance genotypes with patient gender. 
Variable Sex  
Genotypes Male Female Total P-value 
YMDD 
 




4 2 6 
YIDD/ YVDD  
 
0 1 1 












23 8 31 0.336 
 
 
4.2.3  Lamivudine resistance genotypes and lamivudine intake duration  
 The lamivudine intake duration was between 18 and 28 months. The mean Lamivudine 
intake duration was 27 months  in YMDD /YIDD/ YVDD; 24 months in YMDD; and 
approximately the same (20 months) in  YIDD YIDD/YVDD,YIDD/ YMDD(Table 
4.4). The difference between the mean duration was not statistically significant among 
the different lamivudine resistance genotypes (P- value = 0.696). 
Table(4.4): Comparison between the mean lamivudine intake duration and 
Lamivudine resistance genotypes. 
 
Genotypes No. Mean Std. Deviation P-value 
YMDD 11 24.09 13.247 0.696 
YIDD 4 18.50 8.888 
YIDD /YVDD 1 20.00 . 
YMDD / YIDD 19 18.47 13.990 
YMDD / YIDD 
/YVDD 
4 26.75 11.087 




However, a statistically significant difference was obtained by comparing the wild type 
(YMDD) from one side with all of the other resistance genotypes from the other side, 
since P-value was 0.049, as the mean uptake duration was higher  in YMDD than in the 
resistance types (Table 4.5). 
 
Table(4.5): Comparison between the mean of lamivudine intake duration for 
YMDD and all different Lamivudine resistance genotypes. 
 
 
Genotypes No. Mean Std. Deviation Sig. 
YMDD 11 27.36 14.362 0.049 
Other 28 18.43 11.507 
Total 39 20.95 12.843 
 
 
4.2.4 Lamivudine resistance genotypes  and viral load 
The mean of viral load was different with P-value = 0.028 between the detected 
lamivudine resistance genotypes : YMDD/ YIDD /YVDD > YIDD/ YVDD > YMDD/ 
YIDD >YMDD >YIDD (Table 4.6). This difference however was not profound as all 
patients were chosen with already high viral loads. 
Table(4.6): Comparison between the mean viral load and Lamivudine resistance 
genotypes 
 
Genotypes No. Mean Std. Deviation P-value 
YMDD 15 1.07 X 10
8
 2.855 X 10
8
 0.028 
YIDD 6 9.10 X 10
7
 1.208 X 10
8
 
YIDD / YVDD 1 7.28 X 10
8
 . 
YMDD /YIDD 19 2.44 X 10
8
 3.295 X 10
8
 
YMDD /YIDD / 
YVDD 
5 8.02 X 10
8
 1.035 X 10
9
 
Total 46 2.51 X 10
8





This difference was not statistically significant when comparing the wild type (YMDD) 
and the other resistant genotypes collectively, since the P-value was 0.146, although the 
mean was slightly higher in the mutant types than in YMDD (Table 4.7). 
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Table(4.7): Comparison between the mean viral load of YMDD and all different 
Lamivudine resistance genotypes. 
 
Genotypes 
No. Mean Std. Deviation P-value 
YMDD 15 1.07 X 10
8
 2.855 X 10
8
 0.146 
Other 31 3.20 X 10
8
 5.184 X 10
8
 
Total 46 2.51 X 10
8




4.2.5 Relationship between genotypes and liver function test (ALT and AST).  
The mean ALT and AST levels were abnormal in all groups. Although there were some 
intergroup differences in the mean of both ALT and AST levels, no statistically 
significant difference was achieved (Table 4.8). The P-value for ALT was 0.403 and for 
AST was 0.916. 
 
Table (4.8): Comparison between the mean ALT and AST levels and Lamivudine 
resistance genotypes 
 
Genotypes N ALT Mean Std. Deviation Sig. 
YMDD 13 59.15 40.681 0.403 
YIDD 4 45.75 11.057 
YMDD /YIDD 12 79.00 43.229 
YMDD / YIDD / YVDD 2 52.00 15.556 
Total 31 64.65 39.003 
 
Genotypes N AST Mean Std. Deviation Sig. 
YMDD 13 47.92 26.794 0.916 
YIDD 4 53.25 18.554 
YMDD / YIDD 12 51.00 15.457 
YMDD / YIDD / YVDD 2 58.00 1.414 








Similarly, no statistically significant difference was reached by comparing the ALT and 
AST levels between the YMDD wild type group and the resistance genotypes (P-value 
= 0.959 and 0.543 for ALT and AST respectively) (Table 4.9). 
 
Table(4.9): Comparison between the mean ALT and AST levels of YMDD and all 
different Lamivudine resistance genotypes. 
 
Genotypes 
N Mean Std. Deviation Sig. 
ALT YMDD 13 65.08 43.779 0.959 
Other 18 64.33 36.489 
Total 31 64.65 39.003 
AST YMDD 13 47.77 26.756 0.543 
Other 18 52.39 14.869 






















Hepatitis B virus (HBV) remains one of the most common viruses in the world. Thirty 
percent of world's population have contact with or are carriers of HBV (Stefan et al., 
2012).  There are many antiviral drugs that are used to cure HBV or to interrupt HBV 
further transmission, and stop liver damage. The most common one is lamivudine due to 
its good quality in HBV management. On the other hand, the major drawback of long 
term treatment with lamivudine results in amino acids variation in the virus and the 
emergence of drug resistance HBV mutant.  
This study focuses on determining the YIDD and YVDD mutations in HBV DNA 
polymerase due to long term lamivudine among HBV patients, and study factors that 
may be associated with these mutations, In this study we used Real Time PCR in order 
to determine the occurrence of mutants YIDD and YVDD that lead to lamivudine 
resistance as well as the wild type YMDD. This is the first study in Palestine and 
especially in Gaza strip that deals with this issue. The prevalence of lamivudine 
resistance was not previously investigated and their related risk factors were not 
assessed 
 
5.1 Incidence of lamivudine resistance: 
It was found that the genotypes detected in this study may be divided  into five groups. 
The first group is the wild type (YMDD) was found alone in 15 patients out of 46 
patients (32.6%); the second YMDD mixed with YIDD in 19 patients (41.3%); the third 
YIDD alone was found in 6 patients (13%); the fourth YIDD/YVDD in only one patient 
(2.2%) and the fifth YMDD/ /YVDD was (10.9 %). Eight samples were not typable in 
the study, probably, as a result of the presence of other mutations in the PCR primers’ 
binding location. 
Collectively, 31 patients were found to have a lamivudine resistance genotype either 
alone or in combination with the wilde type or another resistance genotype (76.4% of 
the typable samples). This high prevalence rate of lamivudine resistance recorded in our 
study is comparable to other populations like  Brazilians patients,  (67%) (Niesters et 
al., 2005), and Netherland ( 59%) (Pas et al., 2002). On the other hand, it is slightly 
higher than that of other populations such as, Jordan (31%) (Massadeh et al., 2008), 
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and Japan the (31 %) (Kumashiro et al., 2003);. Tuncbilek et al, reported that one tenth 
of chronic hepatitis B virus patients can have lamivudine resistance in Turkey 
(Tuncbilek et al., 2008). 
 
In this research YIDD mutation was more prevalent mutation, than YVDD mutation, the 
prevalence was (45.7% )for YIDD. This agrees with the studies in Jordan (YIDD: 25%, 
YVDD: 6.25%) (Massadeh et al., 2008), Canada (YIDD: 30%) (Allen et al., 1998), 
Netherland (YIDD: 61.5%, YIDD/YVDD: 38.46%) (Pas et al., 2002), Korea (YIDD: 
34%, YVDD: 21.25%) (Jang et al., 2004), two related studies in Japan ( in the first the 
prevalence for YIDD: 54%;  while in the second report YIDD: 20%, YVDD: 5%) 
(Chayama et al., 1998; Kumashiro et al., 2003), and China (36% YIDD and 1 % 
YVDD) (Shi et al., 2006) . On the other hand this result mismatch with other 
investigations, where the prevalence of mutation YVDD was the most dominant 
mutation. For example in Germany (YVDD: 62%, YIDD: 38%) (Zollner et al., 2004), 
Italy (YVDD: 54.2%, YIDD: 29.1%) (Vinceti et al., 2009), Turkey (YVDD: 5.19%, 
YIDD: 2.59%) (Tuncbilek et al., 2008) and in France (Zoulim, 2001) . 
 
 In our study (YIDD mixed with YVDD) was found only in one patient (2.2%), which 
does not correlate with Netherland (YIDD/YVDD: 38.46%)(Pas et al., 2002) and two 
related studies in  China; the first was (YIDD/YVDD: 25%) (Libbrecht et al., 2007), 
while the prevalence of YIDD/YVDD in second study was 14 % ( Wen and Li, 2007). 
This higher prevalence of YIDD may be because it is the first mutation in YMDD 
domain in HBV polymerase. And if the lamivudine treatment continued, the isoleucine 
is replaced by valine in most patients so that as a result formation of YVDD mutant 
(Zollner et al., 2004).  
   
The variant types of mutation may suggest that the transmission of the virus from 
lamivudine treated cases or less likely a spontaneous mutation due to HBV reverse 
transcriptase lacking proofreading activity, so that it is possible that mutation could 
naturally and accidentally occur, even at YMDD motif location (Tsubota, 2006). 
 Also different YMDD mutant rates among studies may reflect the different sensitivities 
and specificities of methods used for detecting YMDD mutants. While the rate of 




5.2 The main factors associated with lamivudine resistance: 
 
5.2.1 Age  
When comparing the different genotypes with each others, or comparing the wild type 
with the other resistance genotypes collectively, there was no statistically significant 
difference with respect to the patient age. This finding correlates with studies in Turkey, 
Germany and China (Zollner et al., 2004; Tuncbilek et al., 2008; Li et al., 2011).In 
this study the mean age of the different genotype groups was close, may be because this 
disease affects any patient in any age if the transmission routes were available. Then the 
infected patients likely will receive lamivudine and the probability for mutations 
occurrence will be profound in these patients in any age if the treatment continue. 
Moreover, the ages of most patients who participated in the study ranged from 20-45 
years, may be due to the fact that most of the Gazian population are young (mean age 
32.35 years) and this age category is usualy more active and more exposed to infections 
with HBV ( El-Ottol et al., 2010). No previous information is available however, about 
the age distribution of HBV patients in Gaza strip. 
   
5.2.2 Gender 
 
The gender distribution of patients participating in the study was similar to that in each 
group of the obtained genotypes. In both cases male patients were more than females.  
This may be related to the fact that males in Palestine are more socially active than 
female. Moreover, they are more exposed to male related risk factors for HBV than 
female like hairdressing. Higher prevalence of HBV among males than females was 
previously reported in Gaza strip (El-Ottol et al., 2010) 
The five combinations of gentoypes obtained in the study did not show a statistically 
significant distribution according to the patient gender such lack of significance was 
also seen in other populations, such as in Turkey, Germany and China (Zollner et al., 








5.2.3 Lamivudine intake duration 
There is no significant relationship between YMDD, YIDD, YIDD /YVDD, 
YIDD/YMDD, (YMDD/YIDD/ YVDD) versus lamivudine intake duration.  
While there is a significant relation between the wild type and  resistant genotypes 
versus lamivudine intake duration since p value was (0.049). As in Germany, there was 
significance between lamivudine resistant patient and the duration time for treatment     
(Zollner et al., 2004). 
 And this agree with many results, when the duration time for treatment prolonged, the 
incidence of lamivudine will be increased. Lamivudine resistance rate is increased from 
14-36 % after one year; in  the next year it is increased to 38%, and in the following two 
years it reaches 49-50% and 66-70% respectively (Zollnere et al, 2004; Sablon and 
Shapiro, 2005; Gupta et al., 2006; Mohanty et al, 2006; Tsubota, 2006). 
 
5.2.4 Viral load. 
In this study, although the mean viral load was statistically significantly different among 
the five genotype groups (P-value =0.028), no clear trend may be noticed other than that 
the viral load is higher whenever the mutation YVDD is present in a group. This 
coincides with study in Germany, there was significance between lamivudine resistant 
patient and the viral load since p value was highly significance 0.0004 (Zollner et al., 
2004).with a common sense, one might expect the resistance genotypes be associated 
with higher viral load because patients become less respondent to therapy, or simply 
because the occurrence of mutation will change the antigenicity of the virus and help it 
evade the host immune response. 
  
On the other hand, no such significance was obtained by comparing the mean viral load 
of the YMDD wild type with the other 4 resistance genotypes collectively. This is in 
agreement with a Brazilian study that showed no significant viral load different between 
those with and without lamivudine resistance mutation . Whereas the infected patients 
with lamivudine  resistance mutation had high HBV load  (Niesters et al., 2005). Also 
in Turkey, the viral load difference between mutation groups also was not statistically 
significant (Tuncbilek et al., 2008). In Netherland, an increase of HBV DNA 
measurement were not indicative for the emergence of lamivudine resistant strains, even 
though an increase of viral load was observed in the mutant  form  ( Pas et al., 2002). 
No significant difference was apparent between mutant copies and viral load in Japan 
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(Tsubota, 2006).Despite all that, a high HBV DNA level presumably will represent a 
predictive factor for lamivudine viral resistance (Lai et al., 1997; Zoulim, 2001).  
 
5.2.5 Liver function tests (ALT and AST). 
Once more, when comparing the different genotypes with each others, or comparing the 
wild type with the other resistance genotypes collectively, there was no statistically 
significant difference in respect to the patient ALT and AST levels. 
 It is worthy to mention that there are some missing data in the patients’ medical 
records, especially data for ALT and AST levels which may influence the quality of the 
analysis. 
The relationship of ALT level with Lamivudine resistance is not clear. In France high 
pretreatment ALT value was significantly associated with an earlier detection of 
polymerase mutant (Zoulim, 2001). On the other hand in Netherland ALT 
measurements were not indicative for the emergence of lamivudine resistant strains 
(Pas et al., 2002). In Turkish patients ALT measurements were higher in lamivudine 
resistant patients than wild type (Tuncbilek et al., 2008).   
 
5.3 Limitations 
Unfortunately, there are missed data in medical records of patients, also  many patients 
were not cooperative. Because of  that, the sample size was small . 
 
In addition for that, the RT-PCR instrument in Remal Clinic was broken down for many 
years, as a result the quantitation of HBV viral load has stopped, and this led to 
difficulties in sample collection.   
 
Finally due to lamivudine resistant, the combination antiviral therapy for chronic 
hepatitis B is likely to be more successful than monotherapy. This includes antiviral 
effects with lower rates of drug resistance. The disadvantages include increased cost of 













Hepatitis B virus is one of the most common blood borne viral infection and remains 
one of the most major global public health problems in the world. This study 
investigated fifty four patients for the prevalence lamivudine resistance and associated 
risk factors. It is the first study in Palestine to tackle this vital issue. 
The following conclusions are drawn from the results of the present study: 
 
 The prevalence was divided in this study into five groups; the first group is the 
wild type (YMDD) it was found in 15 patients from 46 patients (32.6%), then 
YMDD mixed with YIDD in 21 patients (41.3%), the third was YIDD alone it 
was found in 6 patients (13%), the fourth YIDD / YVDD only one patient 
(2.2%), the final group was YMDD / YIDD / YVDD in five patients (10.9%). 
 
 The relationships between YMDD(Wild type), YIDD, YIDD/YVDD,YIDD/ 
YMDD, and (YMDD /YIDD / YVDD) versus risk factors, as well as the relation 
of YMDD and mutant types (other genotypes) with risk factors ,the findings are 
as follows: 
 
1. No significant relationship between YMDD(Wild type), YIDD, 
YIDD/YVDD,YIDD/ YMDD, and (YMDD /YIDD/ YVDD) versus age, sex, 
lamivudine intake duration, and liver function tests (ALT & AST). While the 
significant relation with them was related to viral load. 
 
2. For YMDD(Wild type) and other genotypes (resistant type) versus age, sex, 
viral load, and liver function tests (ALT & AST); the study showed that no 
significant relationship. Whereas the significant relation with them was related 








1. Implementation of a comprehensive infection control program, the components 
of such program include infection control practices especially designed for 
chronic hepatitis B patients, including routine serological testing and 
surveillance, training and education. These practices should be carried out 
routinely for all hepatitis B patients in the medical centers. 
 
2. Continuous training and education are recommended for both staff and patients 
or patient family, the training courses must contain information such as proper 
hand hygiene techniques, proper use of protective equipment, mode of 
transmission of blood borne viruses, infection control practices and drug 
resistance. 
 
3. Intensive efforts must be made to enrich the medical records in the hospitals and 
in the private laboratories.  
 
4. Hepatitis B patients must be tested every three month for viral load by Real 
Time PCR techniques, because there is a good relation between viral load and 
the indication for lamivudine resistance. 
 
5. Adoption of the Real Time PCR method to test hepatitis B patients for 
lamivudine resistance as used in this study in the medical centers for Palestinian 
Ministry of Health (MOH) because of  its increased sensitivity, and this will 
save time and money spent in treatment. 
 
6. Considering other recent hepatitis B drugs in treatment schedule for treating 
patients such as telbivudine, adefovir and tenofovir.  
 
7. Tailoring HBV therapy via using combination of drugs in lamivudine resistance 
patients to reduce the occurrence of other mutations. 
 





1. Increase the sample size to include most patients in Palestine; from West Bank 
and Gaza Strip. 
2. Study the third mutation YSDD in rtM204 in addition to YVDD and YIDD, and 
the common mutation rtL180M mutation. 
3. Examine lamivudine resistance by other molecular technique like direct 
sequence and RFLP (Restriction Fragment Length Polymorphism) in order to 
compare the results. 
4. Consider other possible risk factors that may have association with lamivudine 
resistance like socioeconomic risk.  
5. Further studies are needed to define hepatitis virus's genotypes between hepatitis 


























1.  Allen, M., Deslauriers, M., Andrews, C., et al., Identification and characterization of 
mutations in hepatitis B virus resistant to lamivudine. Hepatology, Vol. 27, No. 6, p: 
1670-7. (1998). 
 
2.  Andre, F., Overview of a 5-year clinical experience with a yeast-derived hepatitis B 
vaccine. Vaccine, Vol. 8, p: S74–8. (1990). 
 
3.  Baron, S., Medical Microbiology, 4th edition, University of Texas Medical Branch at 
Galveston, Texas. (1996). 
 
4.  Basuni, A., Carman, W., HBV vaccine-escape variants. Methods in Molecular 
Medicine, Vol. 95, p: 115-24. (2004). 
 
5.  Beasley, R., Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer, 
Vol. 61,p: 1942–1956. (1988). 
 
6.  Beasley, R., Hwang, L., Lin, C., et al., Hepatocellular carcinoma and hepatitis B virus: 
a prospective study of 22,707 men in Taiwan. The Lancet, Vol. 2, p: 1129–1133. (1981). 
 
7.  Block, T., Guo, H., Guo, J., Molecular virology of hepatitis B virus for clinicians. 
Clinical Liver Disease, Vol. 11, No. 4, p: 685-706. (2007). 
 
8.  Bottecchia, M., Souto, F., Mro, K., et al., Hepatitis B virus genotypes and resistance 
mutation in patients under long term lamivudine therapy characterization of genotype G 
in Brazil. BMC Microbiology, Vol. 8, No. 11, p:1471-2180. (2008). 
 
9.  Bozdayi, A., Eyigun, C., Turkyilmaz, A., et al., A novel pattern (sW195a) in surface 
gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during 
lamivudine therapy and successful treatment with adefovirdipivoxil. Journal of Clinical 
Virology, Vol. 31, No. 1, p: 76-7. (2004). 
 
10.  Chayama, K., Suzuki, Y., Kobayashi, M., et al., Emergence and takeover of YMDD 
motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by 
wild type after cessation of therapy. Hepatology, Vol. 27, No. 6, p: 1711-6.(1998). 
 
11.  Chien, R., Liaw, Y., Nucleos(t)ide analogues for hepatitis B virus: strategies for long-
term success. Best Practice and Research Clinical Gastroenterology, Vol. 22, No. 6, 
p:1081-92. (2008). 
 
12.  Clements, C., Coghlan, B., Creati, M., et al., Global control of hepatitis B virus: does 
treatment-induced antigenic change affect immunization?. Bulletin of the World Health 
Organization, Vol. 88, p:66-73. (2010). 
 
13.  Colonno, R., Genovesi, E., Medina, I., et al., Long-term entecavir treatment results in 
sustained antiviral efficacy and prolonged life span in the woodchuck model. of chronic 
51 
 
hepatitis infection. Infectious Disease, Vol.184, p: 1236–1245. (2001). 
 
14.  Damerow,  H., Yuen, L., Wiegand, J., et al., Mutation pattern of lamivudine resistance 
in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine 
resistance associated mutation pattern. Medical Virology, Vol. 82, No. 11, p:1850-8. 
(2010). 
 
15.  Das, K., Xiong, X., Yang, H., et al., Molecular modeling and biochemical 
characterization reveal the mechanism of hepatitis B virus polymerase resistance to 
lamivudine (3TC) and emtricitabine (FTC). Virology, Vol. 75, No. 10, p:4771-9. (2001). 
 
16.  Datta, S., An overview of molecular epidemiology of hepatitis B virus (HBV) in India 
.Virology Journal, Vol. 5, p:156-156. (2008). 
 
17.  Dienstag, J., Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus 
infections. Springer Seminars inImmuno-pathology, Vol. 3,p: 461–472. (1981). 
 
18.  Dienstag, J., Schiff, E., Wright, T., et al., Lamivudine as Initial Treatment for Chronic 
Hepatitis B in the United States. The New England Journal of Medicine, Vol. 341, 
p:1256-1263. (1999). 
 
19.  Dore, G., Wallace, J., Locarnini, S., et al., Hepatitis B in Australia: responding to a 
diverse epidemic. National Hepatitis B Alliance, Australia. (2006) 
 
20.  El-Gilany, A., El-Fedawy, S., Bloodborne infections among student voluntary blood in 
Mansoura University, Egypt. East Mediterranean Health Journal, Vol.12, No. 6, p: 742-
8. (2006). 
 
21.  El-Hazmi, M., Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among 
blood donors in a teaching hospital in the Central region of Saudi Arabia. Saudi 
Medical journal, Vol. 25, No. 1, p: 26-33. (2004).   
 
22.  El-Ottol, A., Elmanama, A., Ayesh, B., Prevalence and risk factors of hepatitis B and C 
viruses among haemodialysis patients in Gaza strip, Palestine. Virology Journal, 
doi:10.1186/1743-422X-7-210 (2010).  
  
23.  Feng, Z., Yu, X., Lu, Z., et al., Rapid detection of the hepatitis B virus YMDD mutant 
using AllGlo™ probes. International Journal of Clinical Chemistry and Laboratory 
Medicine, Vol. 412, No. 11-12, p:1018-21. (2011). 
 
24.  Fung, S., Lok, A., Treatment of chronic hepatitis B: who to treat, what to use, and for 
how long?. Clinical Gastroenterology and Hepatology, Vol. 2, No.10, p: 839-48. (2004). 
 
25.  Greenberg, D., Pediatric experience with recombinant hepatitis B vaccines and relevant 
safety and immunogenicity studies. Pediatrics Infectious Disease, Vol.12, p: 438–45. 
(1993). 
 
26.  Gunther, S., Fischer, L., Pult, I., et al., Naturally occurring variants of hepatitis B virus. 




27.  Gupta, V., Hussain, J., Vijay, S., Hepatitis-B: recent treatment. JK Science- Journal of 
Medical Education and Research, Vol. 8, No. 1, p:9-13. (2006). 
 
28.  Hall, A., Control of hepatitis by children vaccination. Reviews in medical microbiology, 
Vol. 5, No. 2, p: 123–30. (1994). 
 
29.  Hartman, C., Hager, H., Berkowitz, D., et al., Interferon Treatment in Children with 
Chronic Hepatitis B:an Israeli experience. Israel Medical Association Journal, Vol. 4, 
No.11, p: 914-8. (2002). 
 
30.  Harvy, R., Champe, P., Fisher, B., Microbiology, 2nd edition, Lippincott Williams and 
Wilkins. (2007) 
 
31.  Health Status in Palestine: Ministry of Health Annual Report 2010, State of Palestine 
Ministry of Health (Palestinian health information center), Nablus, Palestine. 
 
32.  Hige, S., Yamamoto, Y., Yoshida, S., et al., Sensitive Assay for Quantification of 
Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic 
Acids. Clinical Microbiology, Vol. 48, No. 12, p : 4487-4494. (2010). 
 
33.  Hussain, K., Lok, A., Hepatitis B virology in Gordon SC. Management of chronic 
viral hepatitis. New York, Marcel Dekker Inc.1-26. (2002) 
 
34.  Jang, H., Cho, M., Heo, J., et al., Oligonucleotide Chip for Detection of Lamivudine-
Resistant Hepatitis B Virus. Clinical Microbiology, Vol. 42, No. 9, p: 4181-8. (2004). 
 
35.  Kay, A., Zoulim, F., Hepatitis B virus genetic variability and evolution .Virus Research, 
Vol. 127, No. 2, p:164-76. (2007). 
 
36.  Kufe, D., Pollock, R., Weichselbaum, R., et al., Holland-Frei Cancer Medicine, 6th 
edition , BC Decker Inc., UAS. (2003). 
 
37.  Kumashiro, R., Kuwahara, R., Ide, T., et al., Subclones of drug-resistant hepatitis B 
virus mutants and the outcome of breakthrough hepatitis in patients treated with 
lamivudine.Intervirology, Vol.,46, No. 6, P: 350-4.(2003). 
 
38.  Lai, C.,Dienstag, J., Schiff, E., et al., Prevalence and clinical correlates of YMDD 
variants during lamivudine therapy for patients with chronic hepatitis B. Clinical 
Infectious Disease, Vol. 36, No. 6, p: 687-96. (2003a). 
 
39.  Lai, C., Ratziu, V., Yuen, M., Poynard, T., Viral hepatitis B . The Lancet, Vol. 362, No. 
9401, p: 2089-94. (2003b). 
 
40.  Li, M., Hou, W., Wo, J., Liu, K., Character of HBV (hepatitis B virus) polymerase gene 
rtM204V/I and rtL180M mutation in patients with lamivudine resistance. Journal of 
Zhejiang University Science B, Vol. 6, No.7, p: 664-7. (2005). 
 
41.  Li, S., Qin, L., Zhang, L., et al., Molecular epidemical characteristics of Lamivudine 
resistance mutations of HBV in southern China. Medical Science Monitor, Vol. 17, No. 




42.  Libbrecht, E., Doutreloigne, J., Velde, H., et al., Evolution of Primary and 
Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-
InfectedPatients during Long-Term Lamivudine Treatment, Assessed by a Line Probe 
Assay. Journal of Clinical Microbiology, Vol. 45, No. 12, p: 3935-41. (2007). 
 
43.  Locarnini, S., HBV drug resistance .15thnternational HIV drug resistance Workshop, 13-
17 June 2006, Sitges, Spain. (2006). 
 
44.  Locarnini, S., Hatzaki, A., Heathcote, J., et al., Management of antiviral resistance in 
patients with chronic hepatitis B. Antiviral Therapy, Vol. 9, p:679–693. (2004). 
 
45.  Lok, A., Mcmahon, B., Chronic Hepatitis B. Hepatology, Vol. 34, No. 6, p: 1225-41. 
(2001). 
 
46.  Lupo, J., Larrat, S., Hilleret, M., et al., Assessment of selective real-time PCR for 
quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and 
comparison with direct sequencing and line probe assays. Journal of Virological 
Methods, Vol. 156, No.1-2, p: 52-8. (2009). 
 
47.  Mahoney, F., Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. 
Clinical Microbiology Reviews, Vol. 12, No. 2, p: 351-66. (1999). 
 
48.  Masaadeh, H., Hayajneh, W., Alqudah, E., Hepatitis B virus genotypes and lamivudine 
resistance mutations in Jordan. World Journal of Gastroenterology, Vol. 14, No. 47, p: 
7231–7234. (2008). 
 
49.  Mast, E., Margolis, H., Fiore, A., et al., A comprehensive immunization strategy to 
eliminate transmission of hepatitis B virus infection in the United States: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 
1: immunization of infants, children, and adolescents. Centers for Disease Control and 
Prevention CDC., MMWR;54 (RR-16) :1–31.(2005). 
 
50.  Mclachlan, A., Molecular biology of hepatitis B virus, 1 edition, CRC Press, Florida, 
USA. (1991). 
 
51.  McMahon, B., Alward, W., Hall, D., et al. Acute hepatitis B virus infection: relation of 
age to the clinical expression of disease and subsequent development of the carrier 
state. Journal of Infectious Disease, Vol. 151, p:599–603. (1985). 
 
52.  McMahon, B., Alberts, S., Wainwright, R., Bulkow, L., Lanier, A., Hepatitis B-related 
sequelae: prospective study of 1400 hepatitis B surface antigen-positive Alaska Native 
carriers. Archives of Internal Medicine, Vol. 150, No. 5, p:1051–4. (1990). 
 
53.  Ministry of Health in Jordan; Health Indicators: Epidemiological Situation. 
http://www.moh.gov.jo/reports_ a.html      (Accessed on 10/5/2012) 
 
54.  Mohanty, S., Kupfer, S., Khiani, V., Treatment of chronic hepatitis B.Nature Clinical 




55.  Niesters, H., Pas, S., Man, R., Detection of hepatitis B virus genotypes and mutants: 
current status. Clinical Virology, Vol. 34, No.1, p: S4-8. (2005). 
 
56.  Ono-Nita, S., Kato, N., Shiratori, Y., et al., YMDD motif in hepatitis B virus DNA 
polymerase influences on replication and lamivudine resistance: A study by in vitrofull-
length viral DNA transfection. Hepatology, Vol. 29, No. 3, p: 939–945. (1999). 
 
57.  Pas, S., Man, R., Fries, E., Osterhaus, A., Niesters, H., The dynamics of mutations in the 
YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine 
treatment as determined by reverse hybridisation . Journal of Clinical Virology, Vol. 25, 
No. 1, p: 63–71. (2002). 
 
58.  Payungporna, S., Tangkijvanichb, P., Jantaradsameea, P., Theamboonlersa, 
A.,Poovorawana, Y., Simultaneous quantitation and genotyping of hepatitis B virus by 
real-time PCR and melting curve analysis. Journal of Virological Methods, Vol. 120, 
No. 2, p :131–140. (2004). 
 
59.  Pollack, J., Ganem, D., Site specific RNA binding by a hepatitis B virus reverse 
transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. 
Virology, Vol. 68, p: 5579-5587. (1994). 
 
60.  Poordad, F., Chee, G., Viral Resistance in Hepatitis B: Prevalence and Management. 
Current Gastroenterology Reports, Vol. 12, No. 1, p: 62–69. (2010). 
  
61.  Ramos, B., Nunez, M., Martin-Carbonero, L., Hepatitis B Virus Genotypes and 
Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. Journal 
of Acquired Immune Deficiency Syndromes, Vol. 44, No. 5, p :557-61. (2007). 
 
62.  Riu, R., Functional Analysis of Hepatitis B Virus Variants with Mutations in the 
Envelope Proteins. Hamburg. (2007). 
 
63.  Rosina, F., Pintus, C., Meschievitz, C., Rizzetto, M., A randomized controlled trial of a 
12-month course of recombinant human interferon-alpha in chronic delta (type D) 
hepatitis: a multicenter Italian study. Hepatology, Vol. 13, p: 1052-1056. (1991). 
 
64.  Sablon, E., Shapiro, F., Advances in molecular diagnosis of HBV infection and drug 
resistance. International Journal of Medical Science, Vol. 2, No. 1, p: 8-16. (2005). 
 
65.  Shaw, T., Bartholomeusz, A., Locarnini, S., HBV drug resistance: Mechanisms, 
detection and interpretation. Hepatology, Vol. 44, No. 3,p: 593-606. (2006). 
 
66.  Shepard, C., Simard, E., Finelli, L., Fiore, A., Bell, B., Hepatitis B Virus Infection: 
Epidemiology and Vaccination. Epidemiologic Reviews, Vol. 28, p:112–125. (2006). 
 
67.  Sherman, M., Shafran, S., Burak, K., et al., Management of chronic hepatitis B: 
consensus guidelines. The Canadian Journal of Gastroenterology, Vol. 21, Suppl C, p: 
5C-24C. (2007). 
 
68.  Shi, M., Yang, Z., Wang, R., et al., Rapid quantitation of lamivudine-resistant mutants 
in lamivudine treated and untreated patients with chronic hepatitis B virus infection. 
55 
 
International Journal of Clinical Chemistry and Laboratory Medicine, Vol. 373,No.1-2, 
p:172-5. (2006). 
 
69.  Stefan, M., Thomas, B., Jürgen, R., Christoph, S., Heiner, W., Hepatology – A Clinical 
Textbook.3
rd
edition, Flying Publisher, Germany. (2012). 
   
70.  Strasfeld, L., Chou, S., Antiviral Drug Resistance: Mechanisms and Clinical 
Implications. Infectious Disease Clinics of North America, Vol. 24, No. 2, P: 413-437. 
(2011). 
 
71.  Summers, J., Smith, P., Horwich, A., Hepadnavirus envelope proteins regulate 
covalently closed circular DNA amplification. Virology, Vol. 64, p:2819–2824. (1990). 
 
72.  Tian, X., Zhao, C., Ren, J., et al., Gene-expression profiles of a hepatitis B small surface 
antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1. 
Journal of General Virology, Vol. 88, No. 11,p: 2966-2976. (2007). 
 
73.  Tsubota, A., How do naturally occurring YMDD-motif mutants influence the clinical 
course of lamivudine-naïve patients with chronic hepatitis B virus infection?. Journal of 
Gastroenterology Hepatology, Vol. 21, No. 12, p: 1783-8. (2006). 
 
74.  Tunçbilek, S., Köse, S., Elaldi, A., Akman, S., Lamivudine resistance in untreated 
chronic hepatitis B patients in Turkey. Turkey Journal Gastroenterology, Vol. 19 No. 2, 
p: 99-103. (2008). 
 
75.  Tuttleman, J., Pourcel, C., Summers, J., Formation of the pool of covalently closed 
circular viral DNA in hepadnavirus-infected cells. Cell, Vol. 47, p: 451-460. (1986). 
 
76.  Tzang, C., Yu, W., Hsun, I., et al., Transcription Repression of Human Hepatitis B 
Virus Genes by Negative Regulatory Element-binding Protein/SON. Journal of 
Biological Chemistry, Vol.  276, No. 26, p: 24059-67. (2001). 
 
77.  Vincenti, D., Solmone, M., Garbuglia, A., Iacomi, F.,Capobianchi, M., A sensitive direct 
sequencing assay based on nested PCR for the detection of HBV polymerase and 
surface glycoprotein mutations. Journal of Virological method, Vol. 159, p: 53-57. 
(2009). 
 
78.  Wang, G., Seeger, C., Novel mechanism for reverse transcription in hepatitis B viruses. 
Virology, Vol.67, p :6507-6512. (1993) 
 
79.  Wen, H., Li, Q., Real-time PCR detection of multiple lamivudine-resistant mutations 
with displacing probes in a single tube. Journal of Clinical Virology, Vol. 38, No. 4, p: 
334-40. (2007). 
 
80.  Wightman, F., Walters, T., Ayres, A., et al., Comparison of Sequence Analysis and a 
Novel Discriminatory Real-Time PCR Assay for Detection and Quantification of 
Lamivudine-Resistant Hepatitis B Virus Strains. Clinical Microbiology, Vol. 42, No. 8, 




81.  Will, H., Reiser, W., Weimer, T., et al., Replication strategy of human hepatitis B virus. 
Virology, Vol. 61, p: 904-911. (1987). 
 
82.  Wong, V., Ip, H., Reesink, H., et al., Prevention of the HBsAg carrier state in newborn 
infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of 
hepatitis-B vaccine and hepatitis-B immunoglobulin.  The Lancet, Vol. 1, No. 8383, p: 
921–6. (1984). 
 
83.  World Health Organization. Hepatitis B. Geneva, 2002 
http://www.who/cds/csr/lyo/2002.hepatitis_a.html. (Accessed on 15/5/2012) 
 
84.  Xiong, X., Flores, C., Yang, H., Toole, J., Gibbs, C., Mutations in hepatitis B DNA 
polymerase associated with resistance to lamivudine do not confer resistance to 
adefovir in vitro. Hepatology, Vol. 28, p:1669-1673. (1998). 
 
 
85.  Ying, C., DeClercq, E., Nicholson, W., Furman, P., Neyts, J., Inhibition of           
T  the replication of the DNA polymerase M550V mutation variant of human hepatitis B 
virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Viral 
Hepatology, Vol. 7, p: 161–65. (2000). 
 
86.  Yuen, M., Fung, J., Wong, D., Lai, C., Prevention and management of drug resistance 
for anti-hepatitis B treatment. Lancet Infectious Disease, Vol. 9, No. 4, p: 256-64. 
(2009). 
 
87.  Zollner, B., Peterson, J., Puchhammer, E., et al., Viral features of lamivudine Resistant 
Hepatitis B genotype A and D. Hepatology, Vol. 39, No. 1, p:42-50. (2004). 
 
88.  Zoulim, F., Detection of hepatitis B virus resistance to antivirals. Journal of Clinical 

















   
75 
 
Appendix B 
  
75 
 
 
Appendix C
 
